In her presentation to trustees, Provost Laura Carlson reiterated the importance of cultivating a growth mindset as the ...

The Nippon India Pharma Fund - Growth has an AUM of 8914.89 crores & has delivered CAGR of 24.48% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.80%. The minimum ...

Even though your first painting might not be all that you hoped for, you feel if you keep working at it, you’ll get better. This is an example of having a growth mindset. Someone who has a fixed ...

Sometimes the challenge isn’t recognizing time’s value; it's sharpening your focus, building a new mindset and owning your ...

India’s pharmaceutical industry, valued at around US$58 billion, is projected to reach US$120-130 billion by 2030 and US$400-450 billion by 2047. Growth is driven by rising lifestyle diseases, an ...

A10 Networks shows revenue growth and profitability in cybersecurity and infrastructure solutions despite macro challenges.

EPS: $1.93, growth of 2%; guidance raised to $7.85 to $8. Gross Margin: Increased 5% across all operating segments. Pharmaceutical and Specialty Solutions Revenue: Decreased 4% to $51 billion ...

Mohit Bansal, an analyst from Wells Fargo, assigned the Buy rating on Ironwood Pharma (IRWD – Research ... combined with a strategic focus on long-term growth, underpin the Buy recommendation ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Nippon India NIFTY Pharma ETF Growth Plan share price previously? Nippon India NIFTY Pharma ETF Growth Plan share ...

FY2025 guidance was reaffirmed, with revenue expected between $815M and $865M and adjusted EBITDA ranging from $24M to $31M. Census is projected to end FY2025 between 7,300 to 7,750 participants.

Piramal Pharma Limited (PPL) is a global pharmaceuticals and wellness company, with operations across 17 manufacturing and development facilities and a distribution network spanning 100+ ...

What is the category of ITI Pharma and Healthcare Fund Direct Growth ? The category of ITI Pharma and Healthcare Fund Direct Growth is Equity - Sector - Healthcare What is the current NAV of ITI ...